Concentration calculations for reconstituted peptides

Mass per volume is the easy part

A 5 mg vial reconstituted with 2 mL of diluent yields 2.5 mg/mL. Reconstituted with 5 mL it yields 1 mg/mL. The arithmetic is trivial; what matters is recording the exact volume added, because a nominal 2 mL delivered from a syringe is frequently 1.9 or 2.1 mL, and that is a 5% error propagating through every downstream dilution.

For work where concentration accuracy matters, reconstitute gravimetrically. Weigh the vial before and after adding diluent and calculate volume from mass, taking density as 1.0 g/mL for aqueous diluents. This removes syringe tolerance from the chain entirely.

Converting to molar concentration

Molar concentration requires the molecular weight, which appears on the certificate of analysis and in the product monograph. Molarity equals mass concentration divided by molecular weight: a 1 mg/mL solution of a peptide with a molecular weight of 1419 g/mol is approximately 705 µM.

Use the free-base molecular weight rather than the salt-form weight unless the certificate states otherwise, and be explicit in your notes about which you used. Papers that report activity in molar terms are assuming free-base mass, and mixing conventions introduces a silent offset of several percent.

The peptide content correction

Labelled strength is usually gross vial mass. The actual peptide fraction — net peptide content — is typically 70% to 90% for TFA-salted material, with the balance made up of counter-ions and residual water. A vial labelled 5 mg with 80% peptide content contains 4 mg of peptide.

For qualitative screening this rarely matters. For any experiment where the reported concentration will be compared with published EC50 values, apply the correction and state it in your methods. Two laboratories reporting different potencies for the same compound are, more often than not, reporting different content conventions.

Aliquoting to avoid freeze-thaw

Once the working concentration is established, split the solution into single use aliquots before freezing. Each freeze-thaw cycle concentrates solutes at the ice boundary and exposes the peptide to transient pH shifts; three or four cycles are enough to produce measurable loss in sensitive sequences.

Label every aliquot with compound, lot, concentration, diluent and date. A tube marked only with a compound name is unusable data six months later.

Working the calculation from net peptide content

The arithmetic is trivial; the input is where errors originate. Concentration equals mass divided by volume, but the mass to use is net peptide content, not the nominal label weight. A vial labelled 10 mg of a TFA salt with 85 percent net peptide content contains 8.5 mg of peptide, and a stock prepared as if it contained 10 mg is 15 percent weaker than recorded — a systematic error that propagates into every value derived from it.

Molar concentration requires the molecular weight of the correct form. The free-acid, amide, acetate and trifluoroacetate forms of one sequence have different masses, and using the wrong one produces a molarity error of a few percent that is small enough never to be noticed and large enough to matter when comparing against published EC50 values.

A worked example: 8.5 mg of net peptide with a molecular weight of 1419 g/mol dissolved in 2 mL gives 4.25 mg/mL, which is 4250 mg/L divided by 1419 g/mol, or approximately 3.0 mmol/L. Every subsequent dilution should be recorded as a factor from that documented stock rather than recalculated from the label.

Verification and the errors serial dilution hides

Where the sequence contains tryptophan or tyrosine, absorbance at 280 nanometres provides an independent check on concentration using the calculated molar extinction coefficient. It takes a minute and catches gross errors — a mis-set pipette, an incomplete transfer, an undissolved fraction — that arithmetic alone cannot.

Serial dilution compounds error geometrically. Five successive ten-fold steps each carrying two percent pipetting error accumulate into a final concentration that can be materially off, and the error is invisible because every tube looks correct. Preparing intermediate concentrations directly from the stock where volumes permit avoids the compounding entirely.

Finally, adsorptive loss behaves exactly like a calculation error and should be excluded before the calculation is blamed. If a verified stock produces a weaker-than-expected response only at the lowest concentrations, the loss is happening in the dilution series, not in the arithmetic.

Worked example

A 10 mg nominal vial of a TFA salt at 85% net peptide content, MW 1419 g/mol, reconstituted in 2 mL.